Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) – Pipeline Review, H1 2018’, provides in depth analysis on Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology and Gastrointestinal under development targeting Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5)

– The report reviews Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics and enlists all their major and minor projects

– The report assesses Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Akshaya Bio Inc

Bavarian Nordic A/S

Etubics Corp

OSE Immunotherapeutics

Vaxon Biotech

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) Overview

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) Companies Involved in Therapeutics Development

Akshaya Bio Inc

Bavarian Nordic A/S

Etubics Corp

OSE Immunotherapeutics

Vaxon Biotech

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) Drug Profiles

CV-301 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DK-001 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ETBX-011 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GI-6207 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oncolytic Virus to Target Carcinoembryonic Antigen for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OSE-2101 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Activate CEACAM5 for Crohn's Disease Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target CEA for Colorectal Cancer Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target CEA for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vbx-016 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vbx-026 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) Dormant Products

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) Discontinued Products

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) Product Development Milestones

Featured News & Press Releases

Jan 25, 2018: OSE Immunotherapeutics Receives Notice of Allowance for New Patent by U.S. Patent and Trademark Office that Further Strengthens Intellectual Property Portfolio Around Tedopi in Immuno-Oncology Applications

Dec 07, 2017: OSE Immunotherapeutics to Resume Accrual in Phase 3 Clinical Trial of Tedopi in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment

Jun 23, 2017: OSE Immunotherapeutics Announces Temporary Pause of Patient Accrual While Continuing Treatment for Patients Already Enrolled In Phase 3 Clinical Trial of Tedopi in Advanced Lung Cancer

Mar 21, 2017: Direct Tumor Vaccination Shown to Induce Anti-tumor Immunity and Increase Survival in a Murine Model of Pancreatic Cancer

Mar 10, 2017: Bavarian Nordic Announces Collaboration to Evaluate CV301 and Tecentriq in Bladder Cancer

Jan 24, 2017: OSE Immunotherapeutics Announces That the Independent Data Monitoring Committee Recommends Continuation of Pivotal Phase 3 Clinical Trial of Tedopi in Non-Small Cell Lung Cancer

Jan 04, 2017: Bristol-Myers, Bavarian Nordic test Opdivo-plus-vaccine combo in lung cancer

Dec 29, 2016: Bavarian Nordic Initiates Trial of CV301 in Combination with Nivolumab in Patients with Lung Cancer

Aug 15, 2016: Bavarian Nordic Announces Drug Supply Agreement with Bristol-Myers Squibb for NSCLC Clinical Study

Feb 22, 2016: First patients enrolled and dosed in the pivotal trial of Phase 3 of the immunotherapy Tedopi for advanced non-small cell lung cancer

Feb 04, 2016: OSE Pharma Announces U.S. Initiation of Atalante 1, the Company’s Global, Pivotal Phase 3 Trial for Tedopi Immunotherapy in Non-Small Cell Lung Cancer

Jan 06, 2016: OSE Pharma Announces Initiation of Its Pivotal Phase 3 Trial of Tedopi in Non-Small Cell Lung Cancer

Sep 29, 2015: OSE Pharma to participate to the Large & Midcap Event in Paris on October 7-8, 2015

Aug 05, 2015: Etubics Platform Shown to Significantly Increase Survival Of End Stage Colorectal Cancer Patients

Jun 22, 2015: Vaxon Biotech granted Japanese patent for new cancer vaccine candidates

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indication, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Akshaya Bio Inc, H1 2018

Pipeline by Bavarian Nordic A/S, H1 2018

Pipeline by Etubics Corp, H1 2018

Pipeline by OSE Immunotherapeutics, H1 2018

Pipeline by Vaxon Biotech, H1 2018

Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd..1), H1 2018

Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports